Topical and oral agents for erectile dysfunction

Journal of the Formosan Medical Association

Volumn 98, Issue 4, 1999, Pages 233-241

  Lue, Tom F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Erectile dysfunction; Oral agent; Prostaglandin E1; Sildenafil

Indexed keywords

APOMORPHINE; CYCLIC AMP; CYCLIC GMP; NITRIC OXIDE; PHENTOLAMINE; PHENTOLAMINE MESYLATE; PRAZOSIN; PROSTAGLANDIN E1; RAUWOLSCINE; SILDENAFIL; TRAZODONE; YOHIMBINE;

ARTERY DILATATION; CLINICAL TRIAL; CORPUS CAVERNOSUM; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; MALE; NOSE CONGESTION; ORAL DRUG ADMINISTRATION; PENIS ERECTION; PENIS PROSTHESIS; REVIEW; SEDATION; TOPICAL DRUG ADMINISTRATION; VERTIGO;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; HUMANS; IMPOTENCE; MALE; MUSCLE, SMOOTH; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES;

EID: 0033020583     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Virag R: Intracavernous injection of papaverine for erectile failure. Lancet 1982;2:938.
2. Lue TF, Takamura T, Schmidt RA, et al: Hemodynamics of erection in the monkey. J Urol 1983;130:1237-41.
3. Lue TF: Physiology of penile erection and pathophysiology of impotence and priapism. In: Walsh PC, Retik AB, Vaughan ED Jr, et al, eds. Campbell's Urology. 7th ed. Philadelphia: WB Saunders, 1997:1157-79.
4. Bosch RJ, Benard F, Aboseif SR, et al: Penile detumescence: characterization of three phases. J Urol 1991;146:867-71.
5. McConnell J; Benson GS; Wood JG. Autonomic innervation of the urogenital system: adrenergic and cholinergic elements. Brain Res Bull 1982;9:679-94.5.
6. Hedlund H, Andersson K: Comparison of the responses to drugs acting on adrenoreceptors and muscarinic receptors in human isolated corpus cavernosum and cavernous artery. J Auton Pharmacol 1985;5:81-8.
7. Diederich W, Stief CG, Lue TF, et al: Norepinephrine involvement in penile detumescence. J Urol 1990;143: 1264-6.
8. Holmquist F, Andersson K, Hedlund H: Actions of endothelin on isolated corpus cavernosum from rabbit and man. Acta Physiol Scand 1990;139:113-22.
9. Saenz de Tejada I, Carson MP, de las Morenas A, et al: Endothelin: localization, synthesis, activity, and receptor types in human penile corpus cavernosum. Am J Physiol 1991;261:H1078-85.
10. Hedlund H, Andersson K, Fovaeus M, et al: Characterization of contraction-mediating prostanoid receptors in human penile erectile tissues. J Urol 1989;141:182-6.
11. Azadzoi KM, Kim N, Brown ML, et al: Endothelium-derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone. J Urol 1992;147:220-5.
12. Steers WD, McConnell J, Benson G: Anatomical localization and some pharmacological effects of vasoactive intestinal polypeptide in human and monkey corpus cavernosum. J Urol 1984;132:1048-53.
13. Saenz de Tejada I, Goldstein I, Azadzoi K, et al: Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989;320:1025-30.
14. Ignarro LJ, Bush PA, Buga GM, et al: Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Comm 1990;170:843-50.
15. Gruetter CA, Barry BK, McNamara DB, et al: Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res 1979;5:211-24.
16. Ignarro LJ, Buga GM, Wood KS, et al: Endothelium derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9.
17. Palmer RMJ, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
18. Ottesen B, Wagner G, Virag R, et al: Penile erection: possible role for vasoactive intestinal polypeptide as a neurotransmitter. BMJ 1984;288:9-11.
19. Kim YC, Kim JH, Davies MG, et al: Modulation of vasoactive intestinal polypeptide (VIP)-mediated relaxation by nitric oxide and prostanoids in the rabbit corpus cavernosum. J Urol 1995;153:807-10.
20. Stief CG, Benard F, Bosch RJ, et al: A possible role of calcitonin-gene-related peptide in the regulation of the smooth muscle tone of the bladder and penis. J Urol 1990; 143:392-7.
21. Kirkeby HJ, Fahrenkrug J, Holmquist F, et al: Vasoactive intestinal polypeptide (VIP) and peptide histidine methionine (PHM) in human penile corpus cavernosum tissue and circumflex veins: localization and in vitro effects. Eur J Clin Invest 1992;22:24-30.
22. Hedlund P, Alm P, Hedlund H, et al: Localization and effects of pituitary adenylate cyclase-activating polypeptide (PACAP) in human penile erectile tissue. Acta Physiologica Scand 1994;150:103-4.
23. Adaikan PG, Ratnam SS: Pharmacology of penile erection in humans. Cardiovasc Intervent Radiol 1988;11: 191-4.
24. Hedlund P, Aszodi A, Fassler R, et al. Erectile dysfunction in cGMP-dependent protein kinase 1-deficient mice. J Urol 1999;161:216.
25. McGrogan I, Lu S, Hipworth S, et al. Mechanisms of cyclic nucleotide-induced relaxation in canine tracheal smoth muscle. Am J Physiol 1995;268:407-13.
26. Fisher DA, Smith JF, Pillar JS, et al. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 1998;273:15559-64
27. 2+ in cultured human corporal smooth muscle cells. Am J Physiol 1992; 263:C373-83.
28. Christ GJ, Brink PR, Melman A, et al: The role of gap junctions and ion channels in the modulation of electrical and chemical signals in human corpus cavernosum smooth muscle. Int J Impotence Res 1993;5:77-96.
29. Fan SF, Brink PR, Melman A, et al: An analysis of the Maxi-K+ (KCa) channel in cultured human corporal smooth muscle cells. J Urol 1995;153:818-25.
30. Heaton JP, Morales A, Owen J, et al: Topical glyceryltrinitrate causes measurable penile arterial dilation in impotent men. J Urol 1990;143:729-31.
31. Wolfson B, Pickett S, Scott NE, et al: Intraurethral prostaglandin E-2 cream: a possible alternative treatment for erectile dysfunction. Urology 1993;42:73-5.
32. Padma-Nathan H, Hellstrom WJG, Kaiser FE, et al: Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997;336:1-7.
33. Lewis R: Combined use of transurethral alprostadil and an adjustable penile constriction band in men with erectile dysfunction: results from a multicenter trial. Int J Impotence Res 1998;10:s49.
34. Reid K, Surridge DH, Morales A, et al: Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet 1987;2:421-3.
35. Morales A, Surridge DH, Marshall PG, et al: Nonhormonal pharmacological treatment of organic impotence. J Urol 1982;128:45-7.
36. Lal S, Tesfaye Y, Thavundayil JX, et al: Apomorphine: clinical studies on erectile impotence and yawning. Prog Neuropsychopharmacol Biol Psychiatry 1989;13: 329-39.
37. Heaton JP, Morales A, Adams MA, et al: Recovery of erectile function by the oral administration of apomorphine. Urology 1995;45:200-6.
38. Saenz de Tejada I, Ware JC, Blanco R, et al: Pathophysiology of prolonged erection associated with trazodone use. J Urol 1991;165:60-3.
39. Montorsi F, Strambi LF, Guazzoni G, et al: Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study. Urology 1994;44:732-6.
40. Korenman SG, Viosca SP: Treatment of vasculogenic sexual dysfunction with pentoxifylline. J Am Geriatr Soc 1993;41:363-6.
41. Gwinup G: Oral phentolamine in nonspecific erectile insufficiency. Ann Intern Med 1988;109:162-3.
42. Goldstein I, Vasomax Study Group: Efficacy and safety of oral phentolamine (Vasomax) for the treatment of minimal erectile dysfunction. J Urol 1998;159:240.
43. Yanaka N, Kotera J, Ohtsuka A, et al. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem 1998;255:291-9.
44. Goldstein I, Lue TF, Padma-Nathan H, et al: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338: 1397-404.
45. Morales A, Gingell C, Collins M, et al: Clinical safety of oral sildenafil citrate in the treatment of erectile dysfunction. Int J Impotence Res 1998;10:69-73.
46. Lue TF: Impotence: a patients' goal-directed approach to treatment. World J Urol 1990;8:67-74.